297 related articles for article (PubMed ID: 25749046)
21. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Yao S; Janku F; Subbiah V; Stewart J; Patel SP; Kaseb A; Westin SN; Naing A; Tsimberidou AM; Hong D; Piha-Paul SA; Shi N; Johnston A; Bomalaski J; Fu S
Br J Cancer; 2021 Apr; 124(9):1533-1539. PubMed ID: 33674736
[TBL] [Abstract][Full Text] [Related]
22. Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L; Savaraj N
Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
[TBL] [Abstract][Full Text] [Related]
23. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
Savaraj N; You M; Wu C; Wangpaichitr M; Kuo MT; Feun LG
Curr Mol Med; 2010 Jun; 10(4):405-12. PubMed ID: 20459375
[TBL] [Abstract][Full Text] [Related]
24. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
[TBL] [Abstract][Full Text] [Related]
25. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
26. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
27. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
[TBL] [Abstract][Full Text] [Related]
28. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
29. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
31. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
33. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
[TBL] [Abstract][Full Text] [Related]
34. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
Bean GR; Kremer JC; Prudner BC; Schenone AD; Yao JC; Schultze MB; Chen DY; Tanas MR; Adkins DR; Bomalaski J; Rubin BP; Michel LS; Van Tine BA
Cell Death Dis; 2016 Oct; 7(10):e2406. PubMed ID: 27735949
[TBL] [Abstract][Full Text] [Related]
35. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
[TBL] [Abstract][Full Text] [Related]
36. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
Wangpaichitr M; Wu C; Bigford G; Theodoropoulos G; You M; Li YY; Verona-Santos J; Feun LG; Nguyen DM; Savaraj N
Anticancer Res; 2014 Dec; 34(12):6991-9. PubMed ID: 25503125
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Beddowes E; Spicer J; Chan PY; Khadeir R; Corbacho JG; Repana D; Steele JP; Schmid P; Szyszko T; Cook G; Diaz M; Feng X; Johnston A; Thomson J; Sheaff M; Wu BW; Bomalaski J; Pacey S; Szlosarek PW
J Clin Oncol; 2017 Jun; 35(16):1778-1785. PubMed ID: 28388291
[TBL] [Abstract][Full Text] [Related]
38. Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
Field GC; Pavlyk I; Szlosarek PW
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903394
[TBL] [Abstract][Full Text] [Related]
39. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
Savaraj N; Wu C; Kuo MT; You M; Wangpaichitr M; Robles C; Spector S; Feun L
Drug Target Insights; 2007; 2():119-28. PubMed ID: 21901069
[TBL] [Abstract][Full Text] [Related]
40. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]